Therapeutic vaccines for chronic diseases: successes and technical challenges. - Wikidata - awgldk - TriplyDB

Therapeutic vaccines for chronic diseases: successes and technical challenges.

Therapeutic vaccines for chronic diseases: successes and technical challenges.

http://www.wikidata.org/entity/Q37926764

about

The contribution of vaccination to global health: past, present and future.Twenty-first century vaccines.Vaccines and global health.Vaccines and future global health needs.Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.Interleukin-1β-Targeted Vaccine Improves Glucose Control and β-Cell Function in a Diabetic KK-Ay Mouse Model.Particle-based platforms for malaria vaccines.Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking.Prophylactic and therapeutic vaccines for obesity.Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes Progress and future opportunities in the development of vaccines against atherosclerosis.Construction and characterization of virus-like particles: a review.VLPs and particle strategies for cancer vaccines.Plant-based vaccines for Alzheimer's disease: an overview.Using viruses as nanomedicines.Antigen delivery by virus-like particles for immunotherapeutic vaccination.Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments.Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.Virus-based nanoparticles as platform technologies for modern vaccines.Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7.The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.Is The Allergen Really Needed in Allergy Immunotherapy?Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine.

P2860

Q33624593-86E3E263-13D0-4B58-A929-15FB7D08AFE3 Q35137112-9AD602A8-1700-4D17-9514-BDF51AC9D305 Q35137116-AD5CF0EF-7FD8-4ABC-8E41-33084A29984B Q35137122-9EA65E2A-5629-4D66-A2D7-7EF1FEC8997D Q35841913-8ED1E534-BCCC-4661-8747-E5E50F4E0D97 Q36010679-04FC1EE3-2DB8-4E2A-8600-596463A95853 Q36396040-F9F86FA3-B1F8-47FD-A784-A616BF4DD782 Q37177679-33CE3F9B-4BFD-4044-862A-9F44E9C36BA8 Q37473523-5BE98DB2-FC14-495A-8A9B-DDD8E8E65015 Q37696415-69F199A9-6730-4E13-82CB-D672C837AD97 Q37835406-71DBB3AA-9E5C-4224-9038-FA6318EF1CB1 Q38045834-9C12EA4B-1A4F-430C-8FF8-C2100F17CB54 Q38152475-9AE30713-FAEC-44F4-BC92-B5E50C2F8F5F Q38176962-8ACAA23E-79BF-4A6A-BDE5-4A424470D38B Q38191282-9E897A11-AD36-4555-B085-0D00E48FBEE3 Q38285854-9B0C10D9-B533-4899-BCBD-147000EC0334 Q38467270-5F88AC35-8C07-4ACF-8374-2FAC997ADB7E Q38685586-34026CBA-E007-49EB-BEFE-FB8B530847D0 Q38702017-FB9CF9AB-128E-4381-872E-0CDC2DA020B8 Q39581494-B526D90B-D9D6-4F50-934D-73C6BF009F97 Q39816694-B8463D4C-B2D2-4A69-9C1A-95F99606FB51 Q40087267-9472EB95-B355-4A5F-99EA-FE3F524F89C4 Q40398444-C45A641D-82E2-4A7A-91E6-613DA0E6B305 Q42730811-0CF11F06-86AE-4AB8-BD84-31447E1662BE Q50334209-0318507C-1682-4311-83BA-3A2D93DC7282

P2860

Therapeutic vaccines for chronic diseases: successes and technical challenges.

http://www.wikidata.org/entity/Q37926764

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapeutic vaccines for chronic diseases: successes and technical challenges.

@en

Therapeutic vaccines for chronic diseases: successes and technical challenges.

@nl

type

label

Therapeutic vaccines for chronic diseases: successes and technical challenges.

@en

Therapeutic vaccines for chronic diseases: successes and technical challenges.

@nl

prefLabel

Therapeutic vaccines for chronic diseases: successes and technical challenges.

@en

Therapeutic vaccines for chronic diseases: successes and technical challenges.

@nl

P1433

Q37926764-24149955-5F41-4762-AEA9-DE7C7A28D418

P1476

Q37926764-5735EC40-0F0E-4BA2-BAAA-0CE01A349DC0

P2093

Q37926764-17EBE420-43A1-4040-9993-3BB1F4882FA5

Q37926764-4126216C-66C6-48FA-8C82-E4BC3D35DA70

P2860

Q37926764-05AA546F-C3B8-4190-B4D6-FB8979C7F222

Q37926764-067BC0A7-96E9-45DF-BF59-80EDE05584CE

Q37926764-067F4CE0-4A74-4EF5-BB70-7F046D8F5805

Q37926764-0C501CDE-1418-4854-AA38-B8D2EA79F123

Q37926764-0F70E070-82F1-48B2-A0CE-DE15C6A6DB0B

Q37926764-137A8C48-75B3-43BB-BC34-D3F346519CF1

Q37926764-14DBE79B-157A-4410-BCE1-306675E2B84C

Q37926764-1E0FCEFC-D268-4562-86DA-A448D04341F2

Q37926764-200A998D-C7A8-432E-8939-0514A6304421

Q37926764-2B1A8F0A-285D-42CF-B5C7-DBB02C9C5C44

P304

Q37926764-C4B36931-2DB8-4014-8177-2A9F4D7E43B8

P31

Q37926764-C209C5B0-941E-4858-8DBD-42CACF59490E

P356

Q37926764-702CB85D-36ED-408D-81D3-921D36FC3D2E

P407

Q37926764-519FC5AC-4C62-4FD9-BFB6-0DE7214405F7

P433

Q37926764-5C2E674A-3364-447D-B150-F05D0EBD2829

P478

Q37926764-06CAAF9F-44C3-453E-82BC-F78329418585

P577

Q37926764-C51257BB-A8C6-4E88-BEE4-56FF35D323BB

P5875

Q37926764-1ED1D238-6F75-473F-9213-793E4DFE9986

P698

Q37926764-D0E3EA69-AF1B-4954-8F80-684158E482E2

P932

Q37926764-B851550F-C9F3-4CF1-9EDF-00B2678A7298

P356

P1433

Philosophical Transactions of the Royal Society B

P1476

Therapeutic vaccines for chronic diseases: successes and technical challenges.

@en

P2093

Gary T Jennings

http://www.w3.org/2001/XMLSchema#string

Martin F Bachmann

http://www.w3.org/2001/XMLSchema#string

P2860

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

Adherence to Medication

Mechanisms linking obesity to insulin resistance and type 2 diabetes

The world health report 2002 - reducing risks, promoting healthy life

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

A vaccine against nicotine for smoking cessation: a randomized controlled trial

Vaccines for cocaine abuse

Structures of virus and virus-like particles.

P304

2815-2822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1098/RSTB.2011.0103

http://www.w3.org/2001/XMLSchema#string

P407

P433

1579

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51621131

http://www.w3.org/2001/XMLSchema#string

P698

21893545

http://www.w3.org/2001/XMLSchema#string

P932

3146783

http://www.w3.org/2001/XMLSchema#string